中国医药健康产业股份有限公司关于子公司参加第十一批全国药品集中采购拟中选的公告

Core Viewpoint - China National Pharmaceutical Group's subsidiary, Tianfang Pharmaceutical, is likely to be selected for the 11th batch of national centralized drug procurement, which will positively impact the company's sales and market share [1][3]. Group 1: Product Information - Tianfang Pharmaceutical's product, Nicorandil tablets, is expected to be selected for centralized procurement [1]. - The procurement cycle for the selected products will last for three years, from the execution date in 2026 until December 31, 2028 [2]. Group 2: Financial Impact - The audited revenue for Nicorandil tablets in 2024 is approximately 52.47 million yuan, while the unaudited revenue for the first half of 2025 is about 15.82 million yuan [3]. - Winning the bid will likely enhance the sales scale of the product, increase market share, and improve the company's brand influence, leading to positive future operating performance [3].